STOCK TITAN

Dyadic to Present at World Vaccine Congress Washington 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Dyadic International (NASDAQ: DYAI), a biotechnology company, announced its CEO, Mark Emalfarb, will present at the World Vaccine Congress in Washington, D.C. from April 4-6, 2023. Emalfarb's presentation, scheduled for April 5, will focus on transforming manufacturing and bridging technology gaps in vaccine production.

Additionally, he will provide an update on the Phase 1 Clinical Trial for the DYAI-100 COVID-19 vaccine. Key trial milestones include completing dosing in February 2023, with no serious adverse events reported and a full study report expected in the second half of 2023.

Positive
  • None.
Negative
  • None.

JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccine Congress in Washington, D.C.

World Vaccine Congress - Washington, D.C., April 4-6, 2023
Walter E. Washington Convention Center
Wednesday, April 5, 2023, 2:40 PM – 3:10 PM EDT
Influenza and respiratory vaccine track
Level 2 Room 202A
“Transforming Manufacturing & Closing the Technology Gap Between Developed and Developing Countries”

Mr. Emalfarb will also provide a status update on our Phase 1 Clinical Trial of DYAI-100 COVID-19 Recombinant Protein Booster Vaccine Candidate:

  • Dosing of both low and high dose groups was completed in February 2023
  • No Serious Adverse Events (SAE’s) have been reported to date
  • A full study report is expected to be available in 2H 2023

If you would like to meet Mr. Emalfarb and connect with Dyadic at this event, you may request a one-on-one meeting at jlavalley@dyadic.com or you can stop by Dyadic’s booth #106 during the event.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.

Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness. 

With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including our lead asset DYAI-100 COVID-19 vaccine candidate, as well as other biologic vaccines, antibodies, and other biological products.

To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit http://www.dyadic.com

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com.

Contact:

Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com


FAQ

What is Dyadic International's recent update regarding the World Vaccine Congress?

Dyadic International's CEO, Mark Emalfarb, will present at the World Vaccine Congress in Washington, D.C. on April 5, 2023.

What will Mark Emalfarb discuss at the World Vaccine Congress?

He will discuss transforming manufacturing and closing technology gaps between developed and developing countries.

What is the status of Dyadic's DYAI-100 COVID-19 vaccine trial?

The Phase 1 Clinical Trial for DYAI-100 is complete with dosing finished in February 2023, and no serious adverse events reported.

When is the full study report for the DYAI-100 vaccine expected?

A full study report for the DYAI-100 vaccine is expected to be available in the second half of 2023.

How can I meet Dyadic International's CEO at the World Vaccine Congress?

You can request a one-on-one meeting with Mr. Emalfarb or visit Dyadic's booth #106 during the event.

Dyadic International, Inc.

NASDAQ:DYAI

DYAI Rankings

DYAI Latest News

DYAI Stock Data

57.40M
20.63M
30.21%
16.01%
0.61%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
JUPITER